Literature DB >> 20558290

Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.

Barry M Markaverich1, Mary Vijjeswarapu, Kevin Shoulars, Mary Rodriguez.   

Abstract

cRNA microarray and real-time PCR (qPCR) studies from our lab identified five Cell Cycle Pathway (CCP) genes (CCNA2, CCNE2, CDC25A, CDKN1B, and PLK-1) as targets for luteolin in PC-3 prostate cancer cells [Shoulars et al., J. Steroid Biochem. Mol. Biol. 118 (2010) 41-50]. In this paper, Ingenuity Pathway Analysis of the microarray data identified 7 luteolin-regulated genes (EGFR, c-Fos, SOS, GRB2, JNK1, MKK4 and RasGAP) in the Epidermal Growth Factor Signaling Pathway (EGFSP) potentially involved in luteolin regulation of CCP genes and cell proliferation. To address these possibilities, we compared the response profiles (RNA and protein) of these EGFSP and CCP genes to luteolin and gefitinib by real-time PCR (qPCR) and Western blot analyses. Luteolin and gefitinib are known antagonists of EGFR-associated tyrosine protein kinase. Thus, the response profiles of EGFR regulated EGFSP or CCP genes should be very similar if genes in both pathways are controlled through this common mechanism of action. Treatment of PC-3 cell with luteolin for 24h caused a 4-fold stimulation of c-Fos gene expression, significant inhibition (p<0.001) of the CCP genes and G2/M arrest. Treatment of PC-3 cells with gefitinib also inhibited most of the CCP genes in a fashion similar to that of luteolin, however, the EGFR antagonist inhibited c-Fos gene expression, stimulated CDKN1B (p27) and arrested the cells in G0/G1. Thus, although the response patterns of most of the CCP genes to luteolin or gefitinib were similar, the effects of the two compounds on EGFSP gene expression and cell cycle arrest were clearly different. Combination studies revealed that the response of EGFSP genes to luteolin was not affected by gefitinib, even though the two compounds were additive with respect to their abilities to inhibit CCNA2, CCNE2, CDC25A and PCNA. These findings suggest that luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase. Conversely, luteolin regulates PC-3 cell proliferation through an EGFR-tyrosine kinase independent mechanism(s), likely involving the epigenetic control of gene EGFSP gene expression through histone H4 binding interactions resulting in the upregulation of c-Fos and p21 gene expression.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558290      PMCID: PMC2949446          DOI: 10.1016/j.jsbmb.2010.06.006

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  54 in total

Review 1.  Nuclear receptor coregulators: cellular and molecular biology.

Authors:  N J McKenna; R B Lanz; B W O'Malley
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

Review 2.  Cyclins and cell cycle checkpoints.

Authors:  D G Johnson; C L Walker
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

3.  Impact of serum parathyroid hormone concentration and its regulatory factors on arterial stiffness in patients undergoing maintenance hemodialysis.

Authors:  Takayuki Suzuki; Katsuhiko Yonemura; Yukitaka Maruyama; Toshiyuki Takahashi; Takako Takita; Mitsuyoshi Furuhashi; Akira Hishida
Journal:  Blood Purif       Date:  2004-05-27       Impact factor: 2.614

4.  Type II oestrogen binding sites in human colorectal carcinoma.

Authors:  M Piantelli; R Ricci; L M Larocca; A Rinelli; A Capelli; S Rizzo; G Scambia; F O Ranelletti
Journal:  J Clin Pathol       Date:  1990-12       Impact factor: 3.411

5.  Type II estrogen receptors in the papillary cystic tumor of the pancreas.

Authors:  A Carbone; F O Ranelletti; A Rinelli; F M Vecchio; L Lauriola; M Piantelli; A Capelli
Journal:  Am J Clin Pathol       Date:  1989-11       Impact factor: 2.493

6.  An endogenous inhibitor of [3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues.

Authors:  B M Markaverich; R R Roberts; M A Alejandro; J H Clark
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

7.  Heterogeneity of estrogen receptors in the cytosol and nuclear fractions of the rat uterus.

Authors:  H Eriksson; S Upchurch; J W Hardin; E J Peck; J H Clark
Journal:  Biochem Biophys Res Commun       Date:  1978-03-15       Impact factor: 3.575

Review 8.  Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents.

Authors:  R Agarwal
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

9.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

10.  Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth.

Authors:  B M Markaverich; R R Gregory; M Alejandro; F S Kittrell; D Medina; J H Clark; M Varma; R S Varma
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

View more
  15 in total

1.  Expression of prostate stem cell antigen is downregulated during flavonoid-induced cytotoxicity in prostate cancer cells.

Authors:  Qiang Zhang; Guangdong Cheng; Hongbin Qiu; Yuexin Wang; Jingtao Wang; Hui Xu; Tao Zhang; Lixin Liu; Ye Tao; Zhongjuan Ren
Journal:  Exp Ther Med       Date:  2017-06-21       Impact factor: 2.447

2.  Global transcriptomic analysis of model human cell lines exposed to surface-modified gold nanoparticles: the effect of surface chemistry.

Authors:  E M Grzincic; J A Yang; J Drnevich; P Falagan-Lotsch; C J Murphy
Journal:  Nanoscale       Date:  2015-01-28       Impact factor: 7.790

3.  Luteolin induces apoptosis by activating Fas signaling pathway at the receptor level in laryngeal squamous cell line Hep-2 cells.

Authors:  Hui Zhang; Xiuguo Li; Yuanyuan Zhang; Xinyong Luan
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-30       Impact factor: 2.503

4.  Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells.

Authors:  Barry M Markaverich; Kevin Shoulars; Mary Ann Rodriguez
Journal:  Int J Biomed Sci       Date:  2011

5.  Effect of luteolin and apigenin on the expression of Oct-4, Sox2, and c-Myc in dental pulp cells with in vitro culture.

Authors:  Lu Liu; Zhengjun Peng; Zezhen Xu; Xi Wei
Journal:  Biomed Res Int       Date:  2015-02-26       Impact factor: 3.411

6.  Discovering hidden connections among diseases, genes and drugs based on microarray expression profiles with negative-term filtering.

Authors:  Jain-Shing Wu; E-Fong Kao; Chung-Nan Lee
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

7.  Dietary flavonoids as therapeutics for preterm birth: luteolin and kaempferol suppress inflammation in human gestational tissues in vitro.

Authors:  Courtney Wall; Ratana Lim; Marin Poljak; Martha Lappas
Journal:  Oxid Med Cell Longev       Date:  2013-06-05       Impact factor: 6.543

8.  Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.

Authors:  Barry M Markaverich; Mary Vijjeswarapu
Journal:  Int J Biomed Sci       Date:  2012-12

9.  Luteolin inhibits migration of human glioblastoma U-87 MG and T98G cells through downregulation of Cdc42 expression and PI3K/AKT activity.

Authors:  Wen-Yu Cheng; Ming-Tsang Chiao; Yea-Jiuen Liang; Yi-Chin Yang; Chiung-Chyi Shen; Chiou-Ying Yang
Journal:  Mol Biol Rep       Date:  2013-05-16       Impact factor: 2.316

10.  Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.

Authors:  Minami A Sakurai; Yuki Ozaki; Daisuke Okuzaki; Yoko Naito; Towa Sasakura; Ayumi Okamoto; Hiroe Tabara; Takao Inoue; Man Hagiyama; Akihiko Ito; Norikazu Yabuta; Hiroshi Nojima
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.